| Keturah Mingledolph, PHARMD | |
|
4295 Jefferson Davis Hwy, Beech Island, SC 29842-4824 | |
| (803) 593-5196 | |
| Not Available |
| Full Name | Keturah Mingledolph |
|---|---|
| Gender | Female |
| Speciality | Pharmacist |
| Location | 4295 Jefferson Davis Hwy, Beech Island, South Carolina |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1730817859 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | 43592 (South Carolina) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Keturah Mingledolph, PHARMD 4050 Brownstone Dr Apt 910, Evans, GA 30809-9133 Ph: () - | Keturah Mingledolph, PHARMD 4295 Jefferson Davis Hwy, Beech Island, SC 29842-4824 Ph: (803) 593-5196 |
News Archive
A just-released study by a team of researchers at the Harvard Medical School finds that a new global payment model being implemented by Blue Cross Blue Shield of Massachusetts (BCBSMA) is meeting its twin goals of slowing the growth in health care costs while simultaneously improving the quality of patient care.
A new study has explored the role of relative humidity in the transmission of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from person to person indoors. The study titled, "An Overview on the Role of Relative Humidity in Airborne Transmission of SARS-CoV-2 in Indoor Environments," is published in the latest issue of the journal Aerosol and Air Quality Research.
Amid the coronavirus disease (COVID-19) global pandemic that is infecting millions of people across the globe, hope sparks as the World Health Organization (WHO) reports that seventy vaccination trials for the novel coronavirus are underway, with three already at the human trial stage.
Janssen-Cilag International NV has announced the submission of a Type II variation application to the European Medicines Agency (EMA), seeking to broaden the existing marketing authorisation for the immunotherapy DARZALEX® (daratumumab) to include treatment of adult patients with relapsed multiple myeloma who have received at least one prior therapy. The expanded indication is based on daratumumab in combination with lenalidomide (an immmunomodulatory agent) and dexamethasone, or bortezomib (a PI) and dexamethasone.
› Verified 4 days ago
Jessica Lynn Wilcox, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 4295 Jefferson Davis Hwy, Beech Island, SC 29842 Phone: 803-593-5196 | |
Dr. Christopher John Thomas, PHARM. D Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 4295 Jefferson Davis Hwy, Beech Island, SC 29842 Phone: 803-593-5196 | |
Cynthia Buist, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 4295 Jefferson Davis Hwy, Beech Island, SC 29842 Phone: 803-593-5196 | |
James H Riddle, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 4380 Jefferson Davis Hwy, Beech Island, SC 29842 Phone: 803-593-5506 Fax: 803-593-8210 | |
Martha Ledbetter Cox, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 4380 Jefferson Davis Hwy, Beech Island, SC 29842 Phone: 803-593-5506 | |
Taylor Champion, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 4295 Jefferson Davis Hwy, Beech Island, SC 29842 Phone: 803-593-5196 |